[Clinical efficacy of fluconazole in urinary tract fungal infections].
Fluconazole, a new antifungal agent was administered to 7 patients with complicated urinary tract fungal infections. Patients were 6 males and 1 female with ages of 29 to 83 years, with underlying conditions of bladder tumor (3 patients), neurogenic bladder (3 patients) and hydronephrosis (1 patient). Urinary fungi identified were Candida albicans in 5 patients and Candida tropicalis in 2 patients over 10(4) CFU/ml. These fungi were isolated at least twice in intervals of 5 to 7 days before treatment. Fluconazole was given either orally (4 patients) or intravenously (3 patients) in a dose of 50 mg per day. Clinical efficacies were excellent in 3 patients, moderate in 3 patients and poor in 1 patient, showing an efficacy rate of 85.7%. Mycologically, 6 Candida out of the 7 were eliminated. No side effects nor abnormal laboratory data were observed. In conclusion, fluconazole is effective and safe in the treatment of urinary tract fungal infections.
Nito
H
H
Department of Urology, Musashino Red Cross Hospital.
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000935:Antifungal Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002177:Candidiasis / Q000188:drug therapy* / Q000382:microbiology; D004341:Drug Evaluation; D004361:Drug Tolerance; D005260:Female; D015725:Fluconazole; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D014230:Triazoles / Q000008:administration & dosage / Q000627:therapeutic use*; D014552:Urinary Tract Infections / Q000188:drug therapy* / Q000382:microbiology
D000935:Antifungal Agents; D014230:Triazoles; D015725:Fluconazole